Postoperative management of reproductive-aged patients with endometrioid ovarian cysts
- Авторлар: Virivskaya E.V.1, Bakhtiyarov K.R.2, Evstratova K.D.3
-
Мекемелер:
- "Clinic Semeinaya" (Family Clinic), Family Healthcare Network
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- Шығарылым: № 12 (2022)
- Беттер: 140-145
- Бөлім: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/250508
- DOI: https://doi.org/10.18565/aig.2022.272
- ID: 250508
Дәйексөз келтіру
Аннотация
Objective: To assess the long-term results of hormone treatment in patients after laparoscopic cystectomy for endometrioid ovarian cyst. Materials and methods: The observational study included 56 reproductive-aged patients after cystectomy for endometrioid cysts. Forty-one (74.4%) patients in Group 1 took dienogest (Zafrilla) at a daily dose of 2 mg. The therapy duration was 24 weeks. Eight (13.9%) patients in Group 2 used Siluette containing dienogest 2 mg for contraception. Seven (11.6%) patients in Group 3 received therapy with gonadotropin-releasing hormone analogues at a dose of 3.75 mg (1 injection) intramuscularly every 28 days for 6 months. A follow-up was continued after 3 and 6 months. The investigators studied the intensity of pain syndrome using a visual analogue scale (VAS) before treatment and during control visits, reproductive outcomes, recurrence of cysts, and side effects (adverse events) of the drugs used. Results: The intensity of pain syndrome was observed to decrease in all the patients during the performed therapy following 3 and 6 months. The rate of pregnancy onset in Group 1 was comparable to that in the gonadotropin-releasing hormone agonist group (17/41 (41.5%) versus 3/7 (42.8%)). Disease relapse was noted in 3/41 (7.3%) women in Group 1, in 2/8 (25%) patients in Group 2, and in 1/7 (14.2%) in Group 3. Adverse events in the patients of all the groups were not an indication for medication discontinuation, were relieved symptomatically, or stopped at later stages of treatment. Conclusion: Depending on the reproductive motivations of patients, they used different drugs in each age group. In this case, it is necessary to take into account the tolerability of a particular drug. Dienogest occupies its own niche in the therapy of endometriosis-associated pelvic pain, dysmenorrhea, and dyspareunia as a long-term postoperative therapy in patients with endometrioid ovarian cysts.
Толық мәтін
![Рұқсат жабық](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Авторлар туралы
Elena Virivskaya
"Clinic Semeinaya" (Family Clinic), Family Healthcare Network
Email: elenglikman@yandex.ru
PhD, leading expert
Kamil Bakhtiyarov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaDr. Med. Sci., Professor at the Department of Obstetrics, Gynecology and Perinatology
Kristina Evstratova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: 290ii2i@mail.ru
student
Әдебиет тізімі
- Shafrir A.L., Farland L.V., Shah D.K., Harris H.R., Kvaskoff M., Zondervan K., Missmer S.A. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 1-15. https://dx.doi.org/10.1016/j.bpobgyn.2018.06.001.
- Сафронова А. С., Буралкина Н.А., Чупрынин В.Д., Черемин М.М. Прогнозирование репродуктивных исходов у пациенток с глубоким эндометриозом после хирургического лечения. Акушерство и гинекология. 2021; 7: 158-64. https://dx.doi.org/10.18565/aig.2021.7.158-164.
- Selcuk S., Cam C., Koc N., Kucukbas M., Ozkaya E., Eser A., Karat eke A. Evaluation of risk factors for the recurrence of ovarian endometriomas. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016; 203: 56-60. https://dx.doi.org/10.1016/j.ejogrb.2016.05.008.
- Филиппова Е.С., Козаченко И.Ф., Адамян Л.В., Дементьева В.О. Влияние хирургического лечения эндометриоидных кист яичников на состояние овариального резерва у женщин репродуктивного возраста. Проблемы репродукции. 2018; 24(4): 7180. https://dx.doi.org/10.17116/repro20182404171.
- Российское общество акушеров-гинекологов (РОАГ). Клинические рекомендации “Эндометриоз”. 2020.
- Cecchino G.N., Cozzolino M., Roque M., Garcia-Velasco J.A. Endometrioma and reproductive issues: a well-informed patient may be the driver for change. Minerva Ginecol. 2020; 72(3): 149-56. https://dx.doi.org/10.23736/S0026-4784.20.04595-5.
- Prefumo F., Rossi A.C. Endometriosis, endometrioma, and ART results: current understanding and recommended practices. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 34-40. https://dx.doi.org/10.1016/j.bpobgyn.2018.01.019.
- Ярмолинская М.И., Русина Е.И., Хачатурян А.Р., Фролова М.С. Клиника и диагностика генитального эндометриоза. Журнал акушерства и женских болезней. 2016; 65(5): 4-21. https://dx.doi.org/10.17816/JOWD6554-21
- Vercellini P., Crosignani P., Somigliana E. Vigano P., Frattaruolo M.P., Fedele L. ‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum. Reprod. 2011; 26(1): 3-13. https://dx.doi.org/10.1093/humrep/deq302.
- Guo S.W. Recurrence of endometriosis and its control. Hum. Reprod. Update. 2009; 15(4): 441-61. https://dx.doi.org/10.1093/humupd/dmp007.
- Iwami N., Kawamata M., Ozawa N., Yamamoto T., Watanabe E., Mizuuchi M. et al. New treatment strategy for endometriosis using progestin-primed ovarian stimulation with dienogest: A prospective cohort study, comparison of dienogest versus dydrogesterone. Reprod. Biol. 2021; 21(1): 100470. https://dx.doi.org/10.1016/j.repbio.2020.100470.
Қосымша файлдар
![](/img/style/loading.gif)